Log In
Print
BCIQ
Print
Print this Print this
 

MuDelta, eluxadoline (JNJ-270189066)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionLocally-acting mu opioid receptor agonist and delta opioid receptor antagonist
Molecular Target Mu opioid receptor (OPRM1) (MOR) ; Opioid receptor delta 1 (OPRD1) (DOR)
Mechanism of ActionMu opioid receptor agonist; Delta opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationIrritable bowel syndrome
Indication DetailsTreat diarrhea-predominant irritable bowel syndrome (IBS-D)
Regulatory Designation

U.S. - Fast Track (Treat diarrhea-predominant irritable bowel syndrome (IBS-D));
U.S. - Priority Review (Treat diarrhea-predominant irritable bowel syndrome (IBS-D))

Partner

Actavis plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today